SOAT1 and Miyoshi myopathy: Overall, these data support the role of an MDSC-oriented therapeutic strategy, which could include JAK/STAT (ruxolitinib), arginase, or phosphodiesterase-5 inhibitors, as well as hypomethylating agents to relieve the immunosuppression and support the activity of concomitant anti-MM (immuno)therapies (Figure 1).